AKG
2-OXOGLUTARIC ACID
Find entries where: AKG
is present as a standalone ligand in 339 entries
as a non-polymer is covalently linked to polymer or other heterogen groups  5 entries
Chemical Component Summary | |
---|---|
Name | 2-OXOGLUTARIC ACID |
Identifiers | 2-oxidanylidenepentanedioic acid |
Formula | C5 H6 O5 |
Molecular Weight | 146.10 |
Type | NON-POLYMER |
Isomeric SMILES | C(CC(=O)O)C(=O)C(=O)O |
InChI | InChI=1S/C5H6O5/c6-3(5(9)10)1-2-4(7)8/h1-2H2,(H,7,8)(H,9,10) |
InChIKey | KPGXRSRHYNQIFN-UHFFFAOYSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 16 |
Chiral Atom Count | 0 |
Bond Count | 15 |
Aromatic Bond Count | 0 |
Drug Info: DrugBank
DrugBank ID | DB08845 |
---|---|
Name | Oxogluric acid |
Groups |
|
Description | Oxogluric acid (α-Ketoglutarate) is not approved for any indication in the world but is an investigational drug in the United States. In the United States a phase I clinical trial is investigating whether oxogluric acid precursors found in nutritional supplements can benefit patients with the metabolic disorder propionic acidemia. Oxogluric acid is sold as a dietary supplement to athletes to improve their performance by helping to remove excess ammonia, but it is not officially approved for this indication and only experimental studies have shown a reduction in ammonia by oxogluric acid in hemodialysis patients. Physiologically, oxogluric acid acts in the Krebs cycle as an intermediate, is involved in transamination reactions during the metabolism of amino acids, forms glutamic acid by combining with ammonia, and reduces nitrogen by combining with it as well. Several experimental studies have also shown that administration of oxogluric acid helped attenuate the decreased synthesis of muscle protein that is often seen post-surgery. |
Synonyms |
|
Indication | α-α-Ketoglutarate is not approved for any indication in the world but is an investigational drug in the United States. The potential indications for α-Ketoglutarate are in patients with the metabolic disorder propionic acidemia and in trauma patients with muscle loss. |
Categories |
|
CAS number | 328-50-7 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Aspartate aminotransferase | MFENITAAPADPILGLADLFRADERPGKINLGIGVYKDETGKTPVLTSVK... | unknown |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
CCDC/CSD | RIZWUS |
PubChem | 51 |
ChEBI | CHEBI:30915 |
ChEMBL | CHEMBL1686 |
Pharos | CHEMBL1686 |